R1 RCM Inc. (NASDAQ:RCM) Stock Holdings Cut by Sunriver Management LLC

Sunriver Management LLC trimmed its holdings in shares of R1 RCM Inc. (NASDAQ:RCMGet Rating) by 19.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,878,721 shares of the healthcare provider’s stock after selling 440,601 shares during the period. R1 RCM comprises approximately 7.6% of Sunriver Management LLC’s investment portfolio, making the stock its 4th largest holding. Sunriver Management LLC’s holdings in R1 RCM were worth $47,889,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. ProShare Advisors LLC raised its stake in shares of R1 RCM by 49.5% during the 4th quarter. ProShare Advisors LLC now owns 41,331 shares of the healthcare provider’s stock worth $1,054,000 after purchasing an additional 13,686 shares during the period. Credit Suisse AG raised its stake in R1 RCM by 10.3% in the 3rd quarter. Credit Suisse AG now owns 134,395 shares of the healthcare provider’s stock valued at $2,958,000 after acquiring an additional 12,551 shares during the period. Renaissance Technologies LLC raised its stake in R1 RCM by 7.9% in the 3rd quarter. Renaissance Technologies LLC now owns 338,530 shares of the healthcare provider’s stock valued at $7,451,000 after acquiring an additional 24,732 shares during the period. Neuberger Berman Group LLC raised its stake in R1 RCM by 2.1% in the 3rd quarter. Neuberger Berman Group LLC now owns 412,189 shares of the healthcare provider’s stock valued at $8,930,000 after acquiring an additional 8,481 shares during the period. Finally, New York State Common Retirement Fund raised its stake in R1 RCM by 5.9% in the 4th quarter. New York State Common Retirement Fund now owns 461,450 shares of the healthcare provider’s stock valued at $11,762,000 after acquiring an additional 25,741 shares during the period. Institutional investors own 41.97% of the company’s stock.

Shares of R1 RCM stock traded down $0.07 during trading hours on Friday, hitting $21.66. The company’s stock had a trading volume of 839,719 shares, compared to its average volume of 1,688,060. The company has a market cap of $6.06 billion, a PE ratio of 69.87, a PEG ratio of 2.49 and a beta of 0.86. The business has a 50 day moving average price of $24.45 and a two-hundred day moving average price of $24.48. The company has a debt-to-equity ratio of 2.06, a quick ratio of 1.54 and a current ratio of 1.54. R1 RCM Inc. has a 12-month low of $18.71 and a 12-month high of $27.86.

R1 RCM (NASDAQ:RCMGet Rating) last announced its earnings results on Monday, May 9th. The healthcare provider reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). R1 RCM had a net margin of 6.64% and a return on equity of 29.44%. The business had revenue of $385.70 million for the quarter, compared to analysts’ expectations of $384.18 million. During the same quarter in the prior year, the company posted ($2.37) earnings per share. The firm’s quarterly revenue was up 12.6% compared to the same quarter last year. As a group, research analysts anticipate that R1 RCM Inc. will post 0.47 earnings per share for the current year.

RCM has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reduced their target price on R1 RCM from $30.00 to $28.00 in a report on Tuesday, May 10th. Robert W. Baird lifted their target price on R1 RCM from $29.00 to $32.00 in a report on Thursday, March 3rd. TheStreet raised R1 RCM from a “d” rating to a “c” rating in a report on Monday, May 9th. Guggenheim initiated coverage on R1 RCM in a report on Wednesday, April 13th. They set a “neutral” rating for the company. Finally, Zacks Investment Research lowered R1 RCM from a “buy” rating to a “hold” rating in a report on Friday, May 13th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $29.25.

R1 RCM Profile (Get Rating)

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.

Recommended Stories

Want to see what other hedge funds are holding RCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for R1 RCM Inc. (NASDAQ:RCMGet Rating).

Institutional Ownership by Quarter for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.